Natera (NTRA) said Wednesday that the trial evaluating its Fetal Focus single-gene noninvasive prenatal test has enrolled more than 2,000 patients, more than doubling enrollment over the past year.

The company said the test screens for 21 genes that are linked to serious early-onset conditions.

Natera said the trial has shown strong early performance results and confirmed outcomes against genetic testing benchmarks, including accurate detection in rare homozygous cases.